DNA methylation heterogeneity attributable to a complex tumor immune microenvironment prompts prognostic risk in glioma

References

• Wenger A, Ferreyra Vega S, Kling T, et al. Intratumor DNA methylation heterogeneity in glioblastoma: implications for DNA methylation-based classification. Neuro Oncol. 2019;21(5):616–24. doi: 10.1093/neuonc/noz011
   Web of Science ®Google Scholar
• Gimenez M, Marie SKN, Oba-Shinjo S, et al. Quantitative proteomic analysis shows differentially expressed HSPB1 in glioblastoma as a discriminating short from long survival factor and NOVA1 as a differentiation factor between low-grade astrocytoma and oligodendroglioma. BMC Cancer. 2015;15(1):481. doi: 10.1186/s12885-015-1473-9
   Google Scholar
• Ostrom QT, Bauchet L, Davis FG, et al. The epidemiology of glioma in adults: a “state of the science” review. Neuro Oncol. 2014;16(7):896–913. doi: 10.1093/neuonc/nou087
   PubMed Web of Science ®Google Scholar
• Braunstein S, Raleigh D, Bindra R, et al. Pediatric high-grade glioma: current molecular landscape and therapeutic approaches. J Neurooncol. 2017;134(3):541–549. doi: 10.1007/s11060-017-2393-0
   PubMed Web of Science ®Google Scholar
• Harris M, Svensson F, Kopanitsa L, et al. Emerging patents in the therapeutic areas of glioma and glioblastoma. Expert Opin Ther Pat. 2018;28(7):573–590. doi: 10.1080/13543776.2018.1494155
   PubMed Web of Science ®Google Scholar
• Morshed RA, Young JS, Hervey-Jumper SL, et al. The management of low-grade gliomas in adults. J Neurosurg Sci. 2019;63(4):450–457. doi: 10.23736/S0390-5616.19.04701-5
   PubMed Web of Science ®Google Scholar
• Choi S, Yu Y, Grimmer MR, et al. Temozolomide-associated hypermutation in gliomas. Neuro Oncol. 2018;20(10):1300–1309. doi: 10.1093/neuonc/noy016
   PubMed Web of Science ®Google Scholar
• Korshunov A, Schrimpf D, Ryzhova M, et al. H3-/IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers. Acta Neuropathol. 2017;134(3):507–516. doi: 10.1007/s00401-017-1710-1
   PubMed Web of Science ®Google Scholar
• Chahal M, Thiessen B, Mariano C. Treatment of older adult patients with Glioblastoma: moving towards the inclusion of a comprehensive geriatric assessment for guiding management. Curr Oncol. 2022;29(1):360–376. doi: 10.3390/curroncol29010032
   Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96. doi: 10.1056/NEJMoa043330
   PubMed Web of Science ®Google Scholar
• Forst DA, Nahed BV, Loeffler JS, et al. Low-grade gliomas. Oncology. 2014;19(4):403–413. doi: 10.1634/theoncologist.2013-0345
   Google Scholar
• Haddad AF, Young JS, Oh JY, et al. The immunology of low-grade gliomas. Neurosurg Focus. 2022;52(2):E2. doi: 10.3171/2021.11.FOCUS21587
   Web of Science ®Google Scholar
• Neftel C, Laffy J, Filbin MG, et al. An integrative model of cellular states, plasticity, and genetics for Glioblastoma. Cell. 2019;178(4):835–849.e21. doi: 10.1016/j.cell.2019.06.024
   PubMed Web of Science ®Google Scholar
• Kim H, Zheng S, Amini SS, et al. Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. Genome Res. 2015;25(3):316–327. doi: 10.1101/gr.180612.114
   PubMed Web of Science ®Google Scholar
• González-García I, Solé RV, Costa J. Metapopulation dynamics and spatial heterogeneity in cancer. Proc Natl Acad Sci, USA. 2002;99(20):13085–13089. doi: 10.1073/pnas.202139299
   PubMed Web of Science ®Google Scholar
• Eder K, Kalman B. Molecular heterogeneity of glioblastoma and its clinical relevance. Pathol Oncol Res. 2014;20(4):777–787. doi: 10.1007/s12253-014-9833-3
   Web of Science ®Google Scholar
• Klughammer J, Kiesel B, Roetzer T, et al. The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space. Nat Med. 2018;24(10):1611–1624. doi: 10.1038/s41591-018-0156-x
   PubMed Web of Science ®Google Scholar
• Pisanic TR 2nd, Athamanolap P, Wang TH. Defining, distinguishing and detecting the contribution of heterogeneous methylation to cancer heterogeneity. Semin Cell Dev Biol. 2017;64:5–17. doi: 10.1016/j.semcdb.2016.08.030
   Web of Science ®Google Scholar
• Kim M, Costello J. DNA methylation: an epigenetic mark of cellular memory. Exp Mol Med. 2017;49(4):e322. doi: 10.1038/emm.2017.10
   PubMed Web of Science ®Google Scholar
• Lister R, Pelizzola M, Dowen RH, et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature. 2009;462(7271):315–22. doi: 10.1038/nature08514
   PubMed Web of Science ®Google Scholar
• Scherer M, Nebel A, Franke A, et al. Quantitative comparison of within-sample heterogeneity scores for DNA methylation data. Nucleic Acids Res. 2020;48(8):e46. doi: 10.1093/nar/gkaa120
   PubMed Web of Science ®Google Scholar
• Elliott G, Hong C, Xing X, et al. Intermediate DNA methylation is a conserved signature of genome regulation. Nat Commun. 2015;6(1):6363. doi: 10.1038/ncomms7363
   Google Scholar
• Sheffield NC, Pierron G, Klughammer J, et al. DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma. Nat Med. 2017;23(3):386–395. doi: 10.1038/nm.4273
   PubMed Web of Science ®Google Scholar
• Li S, Garrett-Bakelman F, Perl AE, et al. Dynamic evolution of clonal epialleles revealed by methclone. Genome Biol. 2014;15(9):472. doi: 10.1186/s13059-014-0472-5
   PubMed Web of Science ®Google Scholar
• Landau DA, Clement K, Ziller M, et al. Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia. Cancer Cell. 2014;26(6):813–825. doi: 10.1016/j.ccell.2014.10.012
   PubMed Web of Science ®Google Scholar
• Lin DC, Mayakonda A, Dinh HQ, et al. Genomic and Epigenomic Heterogeneity of Hepatocellular Carcinoma. Cancer Res. 2017;77(9):2255–2265. doi: 10.1158/0008-5472.CAN-16-2822
   PubMed Web of Science ®Google Scholar
• Mazor T, Pankov A, Johnson B, et al. DNA methylation and somatic mutations converge on the cell cycle and define similar evolutionary histories in brain tumors. Cancer Cell. 2015;28(3):307–317. doi: 10.1016/j.ccell.2015.07.012
   PubMed Web of Science ®Google Scholar
• Kurscheid S, Bady P, Sciuscio D, et al. Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma. Genome Biol. 2015;16(1):16. doi: 10.1186/s13059-015-0583-7
   PubMed Web of Science ®Google Scholar
• Kickingereder P, Neuberger U, Bonekamp D, et al. Radiomic subtyping improves disease stratification beyond key molecular, clinical, and standard imaging characteristics in patients with glioblastoma. Neuro Oncol. 2018;20(6):848–857. doi: 10.1093/neuonc/nox188
   Web of Science ®Google Scholar
• Lee-Chang C, Miska J, Hou D, et al. Activation of 4-1BBL+ B cells with CD40 agonism and IFNγ elicits potent immunity against glioblastoma. J Exp Med. 2021;218(1). doi: 10.1084/jem.20200913
   Web of Science ®Google Scholar
• Curran CS, Bertics PJ. Eosinophils in glioblastoma biology. J Neuroinflammation. 2012;9(1):11. doi: 10.1186/1742-2094-9-11
   Google Scholar
• Yoshihara K, Shahmoradgoli M, Martínez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4(1):2612. doi: 10.1038/ncomms3612
   PubMed Web of Science ®Google Scholar
• Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinf. 2013;14(1):7. doi: 10.1186/1471-2105-14-7
   PubMed Web of Science ®Google Scholar
• Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017;18(1):220. doi: 10.1186/s13059-017-1349-1
   PubMed Web of Science ®Google Scholar
• Wang LB, Karpova A, Gritsenko MA, et al. Proteogenomic and metabolomic characterization of human glioblastoma. Cancer Cell. 2021;39(4):509–528.e20. doi: 10.1016/j.ccell.2021.01.006
   PubMed Web of Science ®Google Scholar
• Gaujoux R, Seoighe C. A flexible R package for nonnegative matrix factorization. BMC Bioinf. 2010;11(1):367. doi: 10.1186/1471-2105-11-367
   PubMed Web of Science ®Google Scholar
• Zheng SC, Breeze CE, Beck S, et al. EpiDISH web server: epigenetic dissection of intra-sample-heterogeneity with online GUI. Bioinformatics. 2020;36(6):1950–1951. doi: 10.1093/bioinformatics/btz833
   Web of Science ®Google Scholar
• Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–7. doi: 10.1038/nmeth.3337
   PubMed Web of Science ®Google Scholar
• Teschendorff AE, Breeze CE, Zheng SC, et al. A comparison of reference-based algorithms for correcting cell-type heterogeneity in epigenome-wide association studies. BMC Bioinf. 2017;18(1):105. doi: 10.1186/s12859-017-1511-5
   PubMedGoogle Scholar
• Leek JT, Johnson WE, Parker HS, et al. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics. 2012;28(6):882–3. doi: 10.1093/bioinformatics/bts034
   PubMed Web of Science ®Google Scholar
• Chakravarthy A, Furness A, Joshi K, et al. Pan-cancer deconvolution of tumour composition using DNA methylation. Nat Commun. 2018;9(1):3220. doi: 10.1038/s41467-018-05570-1
   PubMedGoogle Scholar
• Xie H, Wang M, de Andrade A, et al. Genome-wide quantitative assessment of variation in DNA methylation patterns. Nucleic Acids Res. 2011;39(10):4099–4108. doi: 10.1093/nar/gkr017
   PubMed Web of Science ®Google Scholar
• Biró TS, Néda Z. Gintropy: gini index based generalization of entropy. Entropy (Basel). 2020;22(8):22(8. doi: 10.3390/e22080879
   Web of Science ®Google Scholar
• Mayakonda A, Lin D-C, Assenov Y, et al. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747–1756. doi: 10.1101/gr.239244.118
   PubMed Web of Science ®Google Scholar
• Wu ZB, Cai L, Qiu C, et al. CTL responses to HSP47 associated with the prolonged survival of patients with glioblastomas. Neurology. 2014;82(14):1261–5. doi: 10.1212/WNL.0000000000000290
   Web of Science ®Google Scholar
• Rooney MS, Shukla S, Wu C, et al. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015;160(1–2):48–61. doi: 10.1016/j.cell.2014.12.033
   PubMed Web of Science ®Google Scholar
• Bindea G, Mlecnik B, Tosolini M, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39(4):782–95. doi: 10.1016/j.immuni.2013.10.003
   PubMed Web of Science ®Google Scholar
• Borst J, Ahrends T, Bąbała N, et al. CD4(+) T cell help in cancer immunology and immunotherapy. Nat Rev Immunol. 2018;18(10):635–647. doi: 10.1038/s41577-018-0044-0
   PubMed Web of Science ®Google Scholar
• Park EG, Pyo S-J, Cui Y, et al. Tumor immune microenvironment lncRNAs. Brief Bioinform. 2022;23(1):23(1. doi: 10.1093/bib/bbab504
   Web of Science ®Google Scholar
• Kaminska B, Ochocka N, Segit P. Single-cell omics in dissecting immune microenvironment of malignant gliomas—challenges and perspectives. Cells. 2021;10(9):2264. doi: 10.3390/cells10092264
   Web of Science ®Google Scholar
• Johnson KC, Anderson KJ, Courtois ET, et al. Single-cell multimodal glioma analyses identify epigenetic regulators of cellular plasticity and environmental stress response. Nat Genet. 2021;53(10):1456–1468. doi: 10.1038/s41588-021-00926-8
   Web of Science ®Google Scholar
• Choo M, Mai V-H, Kim HS, et al. Involvement of cell shape and lipid metabolism in glioblastoma resistance to temozolomide. Acta Pharmacol Sin. 2023;44(3):670–679. doi: 10.1038/s41401-022-00984-6
   Web of Science ®Google Scholar
• Zgheib R, Battaglia-Hsu S-F, Hergalant S, et al. Folate can promote the methionine-dependent reprogramming of glioblastoma cells towards pluripotency. Cell Death Dis. 2019;10(8):596. doi: 10.1038/s41419-019-1836-2
   PubMed Web of Science ®Google Scholar
• Verhaak RGW, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98–110. doi: 10.1016/j.ccr.2009.12.020
   PubMed Web of Science ®Google Scholar
• Wang Q, Hu B, Hu X, et al. Tumor evolution of Glioma-Intrinsic gene expression subtypes associates with immunological changes in the microenvironment. Cancer Cell. 2017;32(1):42–56.e6. doi: 10.1016/j.ccell.2017.06.003
   PubMed Web of Science ®Google Scholar
• Sun H, Yin L, Li S, et al. Prognostic significance of IDH mutation in adult low-grade gliomas: a meta-analysis. J Neurooncol. 2013;113(2):277–84. doi: 10.1007/s11060-013-1107-5
   PubMed Web of Science ®Google Scholar
• Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009;118(4):469–74. doi: 10.1007/s00401-009-0561-9
   PubMed Web of Science ®Google Scholar
• Turcan S, Rohle D, Goenka A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 2012;483(7390):479–83. doi: 10.1038/nature10866
   PubMed Web of Science ®Google Scholar
• Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765–73. doi: 10.1056/NEJMoa0808710
   PubMed Web of Science ®Google Scholar
• Liu JK, Lubelski D, Schonberg DL, et al. Phage display discovery of novel molecular targets in glioblastoma-initiating cells. Cell Death Differ. 2014;21(8):1325–39. doi: 10.1038/cdd.2014.65
   PubMed Web of Science ®Google Scholar
• Karachi A, Dastmalchi F, Mitchell DA, et al. Temozolomide for immunomodulation in the treatment of glioblastoma. Neuro Oncol. 2018;20(12):1566–1572. doi: 10.1093/neuonc/noy072
   PubMed Web of Science ®Google Scholar
• Yuan Q, Zuo F-X, Cai H-Q, et al. Identifying differential expression genes and prognostic signature based on subventricular zone involved glioblastoma. Front Genet. 2022;13:912227. doi: 10.3389/fgene.2022.912227
   Web of Science ®Google Scholar
• Tian Y, Liu C, Li Z, et al. Exosomal B7–H4 from irradiated glioblastoma cells contributes to increase FoxP3 expression of differentiating Th1 cells and promotes tumor growth. Redox Biol. 2022;56:102454. doi: 10.1016/j.redox.2022.102454
   Web of Science ®Google Scholar
• Ge X, Wang Z, Jiang R, et al. SCAMP4 is a novel prognostic marker and correlated with the tumor progression and immune infiltration in glioma. Int J Biochem Cell Biol. 2021;139:106054. doi: 10.1016/j.biocel.2021.106054
   Web of Science ®Google Scholar
• Li M, Zou D, Li Z, et al. EWAS Atlas: a curated knowledgebase of epigenome-wide association studies. Nucleic Acids Res. 2019;47(D1):D983–d988. doi: 10.1093/nar/gky1027
   PubMed Web of Science ®Google Scholar
• Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807–12. doi: 10.1126/science.1164382
   PubMed Web of Science ®Google Scholar
• Brennan CW, Verhaak RW, McKenna A, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462–477. doi: 10.1016/j.cell.2013.09.034
   PubMed Web of Science ®Google Scholar
• Aoki K, Nakamura H, Suzuki H, et al. Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro Oncol. 2018;20(1):66–77. doi: 10.1093/neuonc/nox132
   PubMed Web of Science ®Google Scholar
• Draaisma K, Wijnenga MMJ, Weenink B, et al. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients. Acta Neuropathol Commun. 2015;3(1):88. doi: 10.1186/s40478-015-0265-4
   Google Scholar
• Saadeh FS, Mahfouz R, Assi HI. EGFR as a clinical marker in glioblastomas and other gliomas. Int J Biol Markers. 2018;33(1):22–32. doi: 10.5301/ijbm.5000301
   PubMed Web of Science ®Google Scholar
• Smith JS, Tachibana I, Passe SM, et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst. 2001;93(16):1246–1256. doi: 10.1093/jnci/93.16.1246
   PubMed Web of Science ®Google Scholar
• Ruano Y, Ribalta T, de Lope ÁR, et al. Worse outcome in primary glioblastoma multiforme with concurrent epidermal growth factor receptor and p53 alteration. Am J Clin Pathol. 2009;131(2):257–263. doi: 10.1309/AJCP64YBDVCTIRWV
   Web of Science ®Google Scholar
• Song MS, Carracedo A, Salmena L, et al. Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner. Cell. 2011;144(2):187–199. doi: 10.1016/j.cell.2010.12.020
   PubMed Web of Science ®Google Scholar
• Mu M, Niu W, Zhang X, et al. LncRNA BCYRN1 inhibits glioma tumorigenesis by competitively binding with miR-619-5p to regulate CUEDC2 expression and the PTEN/AKT/p21 pathway. Oncogene. 2020;39(45):6879–6892. doi: 10.1038/s41388-020-01466-x
   PubMed Web of Science ®Google Scholar
• Park AK, Kim P, Ballester LY, et al. Subtype-specific signaling pathways and genomic aberrations associated with prognosis of glioblastoma. Neuro Oncol. 2019;21(1):59–70. doi: 10.1093/neuonc/noy120
   PubMed Web of Science ®Google Scholar
• Takeuchi A, Badr MESG, Miyauchi K, et al. CRTAM determines the CD4+ cytotoxic T lymphocyte lineage. J Exp Med. 2016;213(1):123–138. doi: 10.1084/jem.20150519
   PubMed Web of Science ®Google Scholar
• Pearce EL, Mullen AC, Martins GA, et al. Control of effector CD8+ T cell function by the transcription factor eomesodermin. Science. 2003;302(5647):1041–1043. doi: 10.1126/science.1090148
   PubMed Web of Science ®Google Scholar
• Eshima K, Chiba S, Suzuki H, et al. Ectopic expression of a T-box transcription factor, eomesodermin, renders CD4(+) Th cells cytotoxic by activating both perforin- and FasL-pathways. Immunol Lett. 2012;144(1–2):7–15. doi: 10.1016/j.imlet.2012.02.013
   PubMed Web of Science ®Google Scholar
• Kessler T, Berberich A, Sadik A, et al. Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes. Cancer Med. 2020;9(22):8373–8385. doi: 10.1002/cam4.3447
   Web of Science ®Google Scholar
• Kang EM, Yin A-A, He Y-L, et al. A five-CpG signature of microRNA methylation in non-G-CIMP glioblastoma. CNS Neurosci Ther. 2019;25(9):937–950. doi: 10.1111/cns.13133
   Web of Science ®Google Scholar
• Urup T, Gillberg L, Kaastrup K, et al. Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma. Mol Oncol. 2020;14(5):964–973. doi: 10.1002/1878-0261.12660
   Web of Science ®Google Scholar
• Chen KC, Chen P-H, Ho K-H, et al. IGF-1-enhanced miR-513a-5p signaling desensitizes glioma cells to temozolomide by targeting the NEDD4L-inhibited Wnt/β-catenin pathway. PloS One. 2019;14(12):e0225913. doi: 10.1371/journal.pone.0225913
   PubMed Web of Science ®Google Scholar
• Bady P, Kurscheid S, Delorenzi M, et al. The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033. Acta Neuropathol. 2018;135(4):601–615. doi: 10.1007/s00401-018-1810-6
   PubMed Web of Science ®Google Scholar
• Akgül S, Patch A-M, D’Souza RCJ, et al. Intratumoural heterogeneity underlies distinct therapy responses and treatment resistance in Glioblastoma. Cancers (Basel). 2019;11(2):11(2. doi: 10.3390/cancers11020190
   Web of Science ®Google Scholar
• Yeo AT, Rawal S, Delcuze B, et al. Single-cell RNA sequencing reveals evolution of immune landscape during glioblastoma progression. Nat Immunol. 2022;23(6):971–984. doi: 10.1038/s41590-022-01215-0
   Web of Science ®Google Scholar
• Kleijn A, van den Bossche W, Haefner ES, et al. The sequence of Delta24-RGD and TMZ administration in malignant glioma affects the role of CD8(+)T cell anti-tumor activity. Mol Ther Oncolytics. 2017;5:11–19. doi: 10.1016/j.omto.2017.02.002
   PubMed Web of Science ®Google Scholar
• Dejaegher J, Solie L, Hunin Z, et al. DNA methylation based glioblastoma subclassification is related to tumoral T-cell infiltration and patient survival. Neuro Oncol. 2021;23(2):240–250. doi: 10.1093/neuonc/noaa247
   Web of Science ®Google Scholar